The New England Journal of Medicine Publishes Data from Pivotal Phase III Trial of Fremanezumab for the Preventive Treatment of Chronic Migraine

Read More >

Teva to Present Data for AUSTEDO® (deutetrabenazine) Tablets and Other Research at the 2017 Psych Congress

Read More >

Teva Showcases Data Demonstrating Potential of Fremanezumab to Address Significant Unmet Need in Patients with Chronic and Episodic Migraine

Read More >

Teva and the Huntington Study Group Announce Publication of Data for AUSTEDO™ (deutetrabenazine) Tablets in Huntington Disease from ARC-HD Study in JAMA Neurology

Read More >

Teva Announces Publication of AIM-TD Study Results in The Lancet Psychiatry for the Investigational Use of Deutetrabenazine in Tardive Dyskinesia

Read More >

Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint

Read More >

Teva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention

Read More >

Teva Announces Positive Results for Phase III Study of Fremanezumab for the Prevention of Chronic Migraine

Read More >

Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint

Read More >

Teva Announces Publication of ARM-TD Study Results in Neurology® for the Investigational Use of Deutetrabenazine in Tardive Dyskinesia

Read More >

Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD)

Read More >

Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease

Read More >

Teva and the Huntington Study Group Announce Publication of Pivotal Phase III Data on Deutetrabenazine (SD-809) in Huntington Disease from First-HD Trial in JAMA

Read More >

Teva Presents New Data for SD-809 in Huntington Disease at 68th American Academy of Neurology (AAN) Annual Meeting in Vancouver, B.C.

Read More >

Teva to Present New Respiratory Data at the 2016 Academy of Allergy, Asthma and Immunology Annual Meeting

Read More >

Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials

Read More >

Teva and University College London Embark on Unique Brain Imaging Study Aimed at Unlocking a New Approach in Neurodegenerative Disease

Read More >

Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma

Read More >

Teva Announces Breakthrough Therapy Designation for SD-809 Granted by FDA for the Treatment of Tardive Dyskinesia

Read More >

Teva to Present New Respiratory Data at the 2015 Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology

Read More >

Important New Data from Teva's TEV-48125 Phase 2B Migraine Program Published in Lancet Neurology in Back-to-Back Articles

Read More >

Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain

Read More >

Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial

Read More >

Teva to Present New Findings at the American Headache Society (AHS) Meeting – Analysis of Migraine Phase IIb Studies Provides Novel Insights into TEV-48125 Efficacy and Safety in Both Episodic & Chronic Migraine

Read More >

Teva Advances Pipeline of Movement Disorder Assets with Announcement of Positive Top-Line Data from the First Pivotal Study of Investigational Treatment for Patients with Tardive Dyskinesia

Read More >

Teva to Present New Respiratory Data at 2015 Annual International Meeting of the American Thoracic Society

Read More >

Teva Presents Further Data from Phase IIb with TEV-48125 in Chronic Migraine at the International Headache Society Congress (IHC): Efficacy and Safety Results at All Doses and Endpoints Present Robust Case for Progression to Phase III

Read More >

Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS

Read More >

Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.

Read More >

Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia (PHN)

Read More >

Teva’s TEV-48125 Meets Primary and Secondary Endpoints in Episodic Migraine Study, Demonstrating Treatment Concept After a Single Dose

Read More >

Teva Announces FDA Acceptance for Review of NDA for its Investigational Twice-Daily Hydrocodone Bitartrate Extended-Release Tablets with Proprietary Abuse Deterrence Technology

Read More >

Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints

Read More >

The Lancet Respiratory Medicine and AAAAI Publish Positive Data from Phase III Trials of Teva’s Reslizumab for the Treatment of Moderate to Severe Asthma in Patients with Elevated Blood Eosinophils

Read More >

Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting

Read More >

Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg

Read More >

Successful Completion of Phase III Program for Teva’s Reslizumab Two More Phase Iii Studies Support the Benefits of Reslizumab Treatment in Asthma Patients with Eosinophilia

Read More >

Teva’s Reslizumab Delivers Clinically and Statistically Significant Reduction in Asthma Exacerbations in Two Pivotal Phase III Studies

Read More >

Teva Reports Positive Results from Pivotal Phase III Study to Evaluate Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Moderate to Severe Chronic Low Back Pain

Read More >

Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer

Read More >

Pride-HD Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntington’s Disease

Read More >

Newly Published Phase III Exploratory Analysis Suggests Investigational Oral Laquinimod for Multiple Sclerosis May Reduce Brain Damage Caused by Neurodegeneration

Read More >

Teva Reports Top-Line Results from Final Phase III Study of Armodafinil (NUVIGIL®) in Patients with Major Depression Associated with Bipolar I Disorder

Read More >

Phase III Data Published in Annals of Neurology Show That a Higher Concentration Dose of Glatiramer Acetate Given Three Times a Week Reduced Annualized Relapse Rates in the Treatment of Relapsing-Remitting Multiple Sclerosis

Read More >

Teva and Active Biotech Report Positive Results from Phase IIa Study of Laquinimod in Active Lupus Nephritis

Read More >

Teva Presented New Data from Phase III Clinical Trial of Milprosa™ (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive Society

Read More >

First Patient Enrolled in Third Phase III Study of Oral Laquinimod for Relapsing-Remitting Multiple Sclerosis

Read More >

Phase III Study of Teva’s Milprosa™ (Progesterone) Vaginal Ring Published in Fertility and Sterility

Read More >

Teva Announces First Patient Enrolled in Largest Clinical Study to Date Evaluating AZILECT® for Mild Cognitive Impairment in Parkinson's Disease

Read More >

Teva Reports Top-Line Results from Second Phase III Study of Armodafinil (NUVIGIL®) in Patients with Major Depression Associated with Bipolar 1 Disorder

Read More >

Phase III Data for Teva’s QNASL® (beclomethasone dipropionate) Demonstrate Efficacy Profile in Pediatric Patients with Seasonal Allergic Rhinitis

Read More >

Phase IIa Laquinimod Trial Results Show Positive Data for Potential Use in Active Crohn's Disease

Read More >

New Data on Teva's Copaxone® and Laquinimod to Be Highlighted at ECTRIMS/ACTRIMS

Read More >

Significant Reduced Loss of Brain Volume in Multiple Sclerosis Patients Treated with COPAXONE(R)

Read More >

Teva Announces Drug Development Investment in Cocrystal Discovery Inc. for Novel Antiviral Therapeutics

Read More >

Teva Announces Additional Investment in CureTech

Read More >

Teva and Alcobra Announce Phase II Trial of Novel, Non-Stimulant MG01CI for ADHD Meets Primary Endpoint

Read More >

Teva Receives FDA Acceptance of Its New Drug Application for BDP Nasal HFA for the Treatment of Allergic Rhinitis

Read More >

Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment

Read More >

Teva Announces Successful Results of Phase III Study of Its Long-Acting G-CSF Product (Lipegfilgrastim) in Breast Cancer Patients

Read More >

Teva Completes Enrollment in Phase III Multiple Sclerosis Trial Evaluating Glatiramer Acetate Three Times Weekly

Read More >

Teva Announces Data on Granulocyte Colony Stimulating Factor Compounds for the Prevention of Chemotherapy-Induced Neutropenia in Breast Cancer Patients

Read More >

Teva and OncoGenex to Present Data on Custirsen in Prostate Cancer at the 2011 ASCO Annual Meeting

Read More >

Teva and CureTech Announce Positive Phase II Data From CT-011, an Investigational Antibody in Diffuse Large B Cell Lymphoma

Read More >

Teva Pharmaceutical Industries Ltd. Makes Statement on DEFINE Study Results

Read More >

New Study Demonstrated Significant Reduction in Annualized Relapse Rate and Halting of Disability Progression in MS Patients Switching to Copaxone®

Read More >

Oral Laquinimod for Multiple Sclerosis Treatment Significantly Reduced Disease Activity and Disability Progression While Providing Good Safety and Tolerability

Read More >

Teva Announces Presentation of New Data on Multiple Sclerosis and Parkinson's Disease Treatments at 2011 American Academy of Neurology Annual Meeting

Read More >

Teva and OncoGenex Present Preclinical Data on the Activity of its Antisense Compound Custirsen (OGX-011/TV-1011) at the American Association of Cancer Research (AACR) Annual Meeting 2011

Read More >

Teva Announces Results from A Phase III Study for QNAZE™ Nasal Aerosol in Perennial Allergic Rhinitis

Read More >

FDA Issues Complete Response Letter for Lower-Volume Glatiramer Acetate sNDA

Read More >

Teva Announces Successful Results of Phase III Study with Oral Laquinimod For Multiple Sclerosis

Read More >

Teva Highlights QNAZE™ HFA Phase III Data at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology

Read More >

Early Initiation of Treatment with Copaxone® Provides Greater Effects in Delaying Conversion to Clinically Definite MS

Read More >

New Data Evaluating Laquinimod for the Treatment of Multiple Sclerosis Demonstrate Neuroprotective Effects

Read More >

Teva to Present New Data on Copaxone® and laquinimod at the 26th Annual ECTRIMS Congress

Read More >

Teva Provides Update on Status of Neutroval™ (G-CSF) Biologics License Application Submitted to the U.S. Food and Drug Administration

Read More >

Teva and OncoGenex Announce Initiation of Second Phase 3 Trial of Custirsen in Men with Metastatic Prostate Cancer

Read More >

Oral Laquinimod Demonstrated Sustained Efficacy and Safety in Patients with Multiple Sclerosis

Read More >

TEMPO Extension Study Further Demonstrates the Benefits of Azilect® in Early Parkinson's Disease Patients

Read More >

Teva Announces Positive Results From a Study Assessing a New Formulation of COPAXONE®

Read More >

Teva Provides Update on Talampanel for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Read More >

ADAGIO Analysis Demonstrates that the Natural Progression of Clinical Symptoms in Parkinson's Disease May Be Slower in Earlier Stages

Read More >

New Data Suggest Oral Laquinimod May Confer Neuroprotection in Addition to Immunomodulation in the Treatment of Multiple Sclerosis

Read More >

Teva to Present New Data on Multiple Sclerosis and Parkinson's Disease at the 62nd American Academy of Neurology Annual Meeting

Read More >

Copaxone® 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety

Read More >

Teva Announces FDA Accepts BLA for XM02

Read More >

Teva Comments on Positive Results of Phase III Trial in Mediwound's Debrase®

Read More >

Results of ADAGIO Study with AZILECT® in Parkinson's Disease Published in New England Journal of Medicine

Read More >

Copaxone® Significantly Reduced Disease Severity in Long-Term Treated Multiple Sclerosis Patients

Read More >

New Data Highlights Advances in MS Treatment Research

Read More >

New Data Illustrate Novel Mechanism of Action of Laquinimod, An Oral Compound For The Treatment of Multiple Sclerosis

Read More >

Long-Term Study with COPAXONE® Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients

Read More >

Teva to Present New Data on its Innovative Therapies for Multiple Sclerosis and Parkinson's Disease at the Upcoming 2009 American Academy of Neurology Annual Meeting

Read More >

Study Demonstrates that Qvar® is More Likely to Achieve Successful Asthma Control with Less Exacerbations

Read More >

Copaxone® Approved by the FDA for Patients with a First Clinical Event Suggestive of Multiple Sclerosis

Read More >

Teva Completes Enrollment in Laquinimod Phase III Clinical Trial

Read More >

Azilect® Shown To Be A Selective Mao-B Inhibitor

Read More >

Copaxone® Demonstrated Protective Effect in Patients with Clinically Isolated Syndrome Suggestive of Multiple Sclerosis

Read More >

Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity

Read More >

Longest Prospective Study in MS Confirmed Robust Clinical Benefits and Safety of Copaxone®

Read More >

Teva to Present New Treatment Data at World Congress for Multiple Sclerosis

Read More >

ADAGIO Trial Results Show Teva's Azilect® 1 Mg Tablets Slow Progression of Parkinson's Disease

Read More >

Teva Enrolls Patients for a Second Large Global Phase III Trial Of Oral Laquinimod

Read More >

ADAGIO Phase III Top Line Data to be Presented at 12th Congress of European Federation of Neurological Societies

Read More >

Teva Provides Update on FORTE Trial

Read More >

Teva's AZILECT® 1 mg Tablets Meet End Points in ADAGIO Phase III Trial

Read More >

Early Treatment With Copaxone® Significantly Delayed Progression To Clinically Definite Multiple Sclerosis

Read More >

Copaxone® Significantly Reduced Annual Relapse Rates And Stabilized Disease Progression In Relapsing Remitting Multiple Sclerosis Patients Failing Interferon Treatment

Read More >

Teva Provides Update On Glatiramer Acetate 40mg For Amyotrophic Lateral Sclerosis (ALS)

Read More >

Early Treatment with COPAXONE® Demonstrated Robust Protection against Progression to Clinically Definite Multiple Sclerosis in the PreCISe Study

Read More >

Initiation Of Enrollment In Pivotal Phase III Clinical Study Of Oral Laquinimod For Relapsing-Remitting Multiple Sclerosis

Read More >

First Patient Undergoes Expanded Cord Blood Transplant in the ExCell Registration Study of StemEx® for Leukemia and Lymphoma

Read More >

Copaxone® Significantly Decreases Disease Activity In Patients Who Switched From Interferon Beta (Ifnb) Due To Development Of Neutralizing Antibodies (Nabs)

Read More >

Long-Term Study Shows Copaxone® Significantly Slows Progression Of Disability And Reduces Relapse Rates In Patients With Relapsing-Remitting Multiple Sclerosis

Read More >

Teva Provides Update On Edratide For Systemic Lupus Erythematosus

Read More >

Teva And Active Biotech To Initiate Pivotal Phase III Trial Program Of Oral Laquinimod For Relapsing Multiple Sclerosis

Read More >

Laquinimod, A Novel Oral Compound, Showed Significant Reduction In Disease Activity In Patients With Relapsing - Remitting Multiple Sclerosis (RRMS)

Read More >

Data Published In Neurology Showed That Higher Dose Of Copaxone® Increased Efficacy In Relapsing-Remitting Multiple Sclerosis (Rrms)

Read More >
Loading...